In a 52-year-old woman taking ciprofloxacin who develops hematuria, has a positive urinalysis, a normal comprehensive metabolic panel, and an elevated white blood cell count with neutrophilia, what is the appropriate management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Hematuria in a 52-Year-Old Woman on Ciprofloxacin

Stop ciprofloxacin immediately and obtain urine culture with susceptibilities to guide alternative antibiotic therapy, as ciprofloxacin is a rare but documented cause of drug-induced hematuria and more serious hematologic complications.

Clinical Assessment

This patient presents with hematuria while on ciprofloxacin for a presumed urinary tract infection (UTI), with laboratory findings showing:

  • Leukocytosis (WBC 13.3 × 10⁹/L) with neutrophilia (10.1 × 10⁹/L)
  • Normal comprehensive metabolic panel (ruling out acute kidney injury)
  • Positive urinalysis

The elevated WBC with neutrophilia suggests either ongoing infection or a systemic inflammatory response 1. The normal renal function is reassuring but doesn't exclude drug-induced urologic complications.

Immediate Actions

1. Discontinue Ciprofloxacin

Ciprofloxacin has been directly associated with hematuria in case reports 2, and more seriously, with hemolytic-uremic syndrome (HUS) 3 and thrombotic thrombocytopenic purpura (TTP) 4. While rare, these are life-threatening complications that present with hematuria, thrombocytopenia, and microangiopathic hemolytic anemia. The FDA drug label for ciprofloxacin notes that crystalluria can occur, particularly in alkaline urine, which may contribute to hematuria 5.

2. Obtain Urine Culture Before Switching Antibiotics

A urine culture and susceptibility testing must be performed before initiating alternative therapy 6, 7. This is critical for:

  • Confirming bacterial UTI versus other causes of hematuria
  • Identifying the causative organism
  • Guiding appropriate antibiotic selection based on susceptibilities

3. Rule Out Serious Hematologic Complications

Check immediately:

  • Complete blood count with peripheral smear (looking for schistocytes, thrombocytopenia)
  • Lactate dehydrogenase (LDH)
  • Haptoglobin
  • Direct Coombs test

If schistocytes are present with thrombocytopenia and elevated LDH, this suggests TTP/HUS and requires urgent hematology consultation and plasmapheresis 3, 4.

Antibiotic Management

Determine Infection Severity

For uncomplicated cystitis (if no fever, flank pain, or systemic symptoms):

  • First-line alternatives include nitrofurantoin (100 mg twice daily for 5-7 days) or trimethoprim-sulfamethoxazole (160/800 mg twice daily for 3 days) if local resistance is <20% 6
  • Fosfomycin (3g single dose) is another option 6

For pyelonephritis (if fever, flank pain, or systemic symptoms present): Given the leukocytosis and neutrophilia, consider pyelonephritis. The patient requires:

  • If fluoroquinolone resistance is <10% locally: Switch to oral levofloxacin 750 mg daily for 5 days OR continue ciprofloxacin only if culture confirms susceptibility and hematuria resolves after stopping initial course 6, 7, 6
  • If fluoroquinolone resistance is >10% or unknown: Administer one-time IV dose of ceftriaxone 1g, then oral cefpodoxime 200 mg twice daily for 10 days 6, 7, 6
  • If organism susceptibility is known: Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 14 days is appropriate if susceptible 6

Important Caveat About Fluoroquinolones

While fluoroquinolones (including ciprofloxacin) are highly effective for UTIs 6, 7, guidelines recommend reserving them for more serious infections due to collateral damage (resistance development) and adverse effects 6. In this case, the temporal association between ciprofloxacin use and hematuria development makes continuing any fluoroquinolone inadvisable unless absolutely necessary based on culture results.

Additional Evaluation for Hematuria

Hydration Status

Ensure adequate hydration to prevent crystalluria, which can occur with ciprofloxacin and other antibiotics 5. The patient should maintain urine output >1.5 liters daily.

Imaging Considerations

If hematuria persists after stopping ciprofloxacin and treating the infection:

  • Obtain renal ultrasound to evaluate for obstruction, stones, or structural abnormalities 7, 8
  • Consider CT urography if risk factors for malignancy exist (age >35, smoking history, gross hematuria) 8

Cystoscopy

Gross hematuria in a 52-year-old woman warrants cystoscopy evaluation, particularly if hematuria persists after infection treatment, as malignancy risk is 2.6-4% in microhematuria and up to 30-40% in gross hematuria 8.

Monitoring

  • Repeat urinalysis 48-72 hours after stopping ciprofloxacin to assess hematuria resolution
  • Repeat CBC to ensure WBC normalizes with appropriate antibiotic therapy
  • If hematuria persists beyond infection treatment, proceed with urologic evaluation including imaging and cystoscopy 8

Common Pitfalls to Avoid

  1. Don't continue ciprofloxacin without culture confirmation - The temporal relationship between drug initiation and hematuria development suggests drug causation
  2. Don't assume all hematuria is from infection - While UTI is likely given the positive UA and leukocytosis, drug-induced causes and underlying urologic pathology must be excluded
  3. Don't delay culture collection - Obtain culture before switching antibiotics to guide definitive therapy 6, 7
  4. Don't miss TTP/HUS - Check for thrombocytopenia and hemolysis, as these are medical emergencies requiring immediate intervention 3, 4

Related Questions

In a 32‑year‑old man with a history of marijuana use who presents with right‑leg tingling, leukocytosis (white blood cell count 12.7 ×10⁹/L) with absolute neutrophil count 10,668/µL, albumin 5.2 g/dL, and normal erythrocyte sedimentation rate and C‑reactive protein, what is the appropriate initial diagnostic work‑up and management?
How should I manage a 32-year-old male presenting with myalgias, serum albumin 5.2 g/dL, leukocytosis (WBC 12.7 ×10⁹/L), and neutrophilia (absolute neutrophil count 10,668/µL)?
What is the appropriate management for a 36-year-old woman with new marked leukocytosis (WBC 22.1 ×10⁹/L, absolute neutrophil count 17.0 ×10⁹/L), thrombocytosis (platelets 572 ×10⁹/L), mild hypokalemia (potassium 3.4 mmol/L), low bicarbonate (CO₂ 19 mmol/L), elevated alkaline phosphatase (159 U/L), dyslipidemia (LDL 143 mg/dL, HDL 39 mg/dL, total cholesterol 204 mg/dL), vitamin D insufficiency (24.4 ng/mL), and well‑controlled type 2 diabetes (A1c 5.3 %)?
Does a man with 4-6 WBC (White Blood Cells) in urine and a positive E. coli (Escherichia coli) urine culture require antibiotic treatment?
What is the most likely diagnosis in a 65-year-old woman presenting with progressive fatigue, supraclavicular lymphadenopathy, a markedly elevated white‑blood‑cell count predominantly lymphocytic, and peripheral smear showing small mature lymphocytes?
After my catheter was removed, I voided a larger amount on day 1 but still had a post‑void residual of about 295 mL, and on day 2 I can only pass 50‑100 mL per void and find urination difficult—what could be causing this and how should I manage it?
What are the drug interactions of ropinirole (Requip)?
What does a high aldosterone-to-renin ratio indicate, and what are the recommended confirmatory tests and management steps for primary aldosteronism?
After ureteroscopy with intracorporeal lithotripsy, what happens to multiple stone fragments smaller than 4 mm after ureteral stent removal?
What volume of intravenous fluid is recommended for patients with necrotizing pancreatitis?
How does cluster dextrin (highly branched cyclic dextrin) compare to maltodextrin in terms of absorption rate, glycemic impact, osmolality, gastrointestinal tolerance, and recommended dosing for athletes?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.